dots health software glp-1 Why a Companion App Is a Necessity The expanding landscape of GLP-1

According to the SURMOUNT-1 clinical trial, patients using tirzepatide at the highest dose (15 mg weekly) experienced up to 22.5% total body weight loss over 72 weeksgreater than what is typically seen with semaglutide GLP-1

More precisely, in early clinical trials, Retatrutide has shown the potential for significant weight loss, with participants on the highest dose losing an average of 28.7% of their body weight over 68 weeks, which is double the weight loss seen with other GLP-1 medications like Ozempic and Wegovy

Patients often use the names interchangeably online, but the medical and insurance distinction matters

Serving Round Rock, Cedar Park, Georgetown, Pflugerville, Austin, and all of Texas via telehealth

Non-Sexual Applications Hemorrhagic Shock : By activating MC1R and MC4R, PT-141 mitigates ischemic damage and supports tissue recovery in low-oxygen conditions (4)

B., & Haupt, A